ATAI Life Sciences (Munich & Berlin, Germany; Florian Brand is CEO) billionaire tech investor Peter Thiel led a $125 million funding round. The company is developing a drug development platform for innovative mental health solutions and backs psychedelic and conventional therapies. ATAI says its model “combines funding, access to accelerative platform technologies, as well as scientific and regulatory expertise.” Several of its drugs are currently in Phase 2 trials.
Cybin Inc (Boston, MA; Doug Drysdale CEO) biotech company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions
Compass Pathways (Altrincham & London, England; Dr. George Goldsmith) mental health care and psilocybin; one of the bigger, more well-funded companies in the space
MindMed (San Francisco, CA; JR Rahn) deploying psy med via FDA clinical trials; wearables to understand the benefits of microdosing LSD; in March 2020, MindMed was the first psychedelics pharmaceutical firm to go public via an IPO on the Neo Exchange (Canada); they are financially backed partly by Kevin O’Leary (Shark Tank); MindMed is in turn funding the creation of the NYU Psychedelic Medicine program; MindMed has partnered with Mindshift Compounds AG
Numinus Wellness Inc (Vancouver, BC, Canada; Payton Nyquvest chairman & CEO) the first publicly traded company in Canada authorized to conduct research on psilocybin extraction. Numinus has a dealer’s license which allows the company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline, as well as produce and extract psilocybin from mushrooms. Numinus is seeking to expand the license to include activities such as import/export, testing and R&D. The expanded license will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through the supply and distribution of these substances.